Sign in
CompletedNo phase

Antireflux Ablation of the Cardia Mucosa vs Placebo for the Treatment of Gastroesophageal Reflux Disease

Key facts

Who runs it
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Where
Spain9 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
64 people enrolled
Started
1 Mar 2021
Ended
7 Feb 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ARMA (antireflux ablation of the cardiac mucosa)
  • upper digestive endoscopy
Record updated
24 April 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Age over 18 years
  • GERD symptoms lasting more than 6 months, not necessarily consecutive. They should at least have a typical GERD symptom (heartburn or regurgitation)
  • Total acid exposure time> 6% in pH measurement study without PPI treatment
  • Patients who do not want to take PPIs or with chronic consumption, defined as PPI consumption of more than 6 months (consecutive or not) in the last 2 years
  • Response to PPI treatment, defined as an increase of> 10 points on the GERD-HRQL questionnaire 15 days after discontinuation of the PPI
  • Written informed consent to participate in the study

Who cannot take part

  • Esophagogastric surgery or previous endoscopic antireflux technique
  • Previously known coagulopathy
  • Oncological disease
  • Severe psychiatric disorder
  • Age> 75 years
  • Patients with sliding hiatal hernia> 2 cm
  • Presence of only atypical GERD symptoms
  • Grade D peptic esophagitis
  • Body mass index> 35 40 kg / m2
  • Liver cirrhosis
  • Pregnancy
  • Incomplete relaxation of the LES in MAR (PIR> 15 mmHg)
  • Absent peristalsis, defined as 100% failed waves with DCI <100 mmHg * cm * s in MAR
  • Barrett's esophagus with dysplasia
  • Esophageal strictures or ulcers
  • Severe cardiopulmonary comorbidity (ASA functional class IV-V)
  • Refusal to participate in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The ARMA technique improves GORD-related quality of life with a low proportion of adverse effects.

The 2 groups in the trial

  • (ARMA) antireflux ablation of the cardiac mucosaTreatment being tested

    The ARMA (Ablation with electrocoagulation current or by argon gas fulguration) technique will be performed in patients assigned to this treatment arm.

  • upper digestive endoscopyPlacebo, for comparison

    Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Double-blind, Placebo-controlled Clinical Trial on the Efficacy of Antireflux Ablation of the Cardiac Mucosa for the Treatment of Gastroesophageal Reflux Disease
Publications
Record updated
24 April 2025